Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCMA CAR-T (Institute of Hematology & Blood Diseases Hospital)
- Development stage
- Unknown
- Lead developer
- Institute of Hematology and Blood Diseases Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
BCMA CAR-T (Institute of Hematology & Blood Diseases Hospital) is an autologous chimeric antigen receptor (CAR) T-cell therapy designed to target the B-cell maturation antigen (BCMA), a protein highly expressed on the surface of malignant plasma cells in multiple myeloma. Developed by the Institute of Hematology & Blood Diseases Hospital of the Chinese Academy of Medical Sciences, the therapy involves the genetic modification of a patient's own T cells to express a CAR that recognizes and binds to BCMA (TNFRSF17). Upon re-infusion, these engineered T cells identify and eliminate myeloma cells, inducing a targeted anti-tumor immune response. This specific CAR-T product is being evaluated in clinical trials, such as the MAGIC-TIEMM study, as part of advanced immunotherapy strategies for newly diagnosed and ultra-high-risk multiple myeloma, often integrated with other modalities like bispecific antibodies or autologous stem cell transplantation.
- Other names
- BCMA CAR-TBCMA-directed CAR-T cellsautologous BCMA-directed CAR-T cells
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on BCMA CAR-T (Institute of Hematology & Blood Diseases Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCMA CAR-T (Institute of Hematology & Blood Diseases Hospital).